Skip to main content
. 2018 Aug 24;7(8):64. doi: 10.1038/s41389-018-0075-1

Fig. 3. Interaction of EGFR, HER2, and PTPIP51 under Gefitinib, Lapatinib, Neratinib, and Mubritinib treatment.

Fig. 3

Interaction of EGFR and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Gefitinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (a). Interaction of HER2 and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Gefitinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (b). Interaction of EGFR and HER2 in SK-BR3 and BT474 cells treated with 5 µM Gefitinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (c). (N = 3)